--- title: "Ono Pharmaceutical (OTCMKTS:OPHLF) Trading Up 14.5% - Should You Buy?" type: "News" locale: "en" url: "https://longbridge.com/en/news/275938196.md" description: "Ono Pharmaceutical (OTCMKTS:OPHLF) saw a 14.5% increase in stock price, reaching $18.67, with a trading volume of 300 shares. The company reported $0.40 earnings per share, exceeding estimates, and revenue of $892.70 million. Ono specializes in innovative therapies, particularly in oncology and immunology, and has a market cap of $8.77 billion. Analysts currently rate the stock as a Hold, suggesting there may be better investment options available." datetime: "2026-02-13T19:22:36.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/275938196.md) - [en](https://longbridge.com/en/news/275938196.md) - [zh-HK](https://longbridge.com/zh-HK/news/275938196.md) --- # Ono Pharmaceutical (OTCMKTS:OPHLF) Trading Up 14.5% - Should You Buy? Ono Pharmaceutical Co. (OTCMKTS:OPHLF - Get Free Report) was up 14.5% on Friday . The stock traded as high as $18.67 and last traded at $18.67. Approximately 300 shares were traded during mid-day trading, a decline of 31% from the average daily volume of 433 shares. The stock had previously closed at $16.30. Get **Ono Pharmaceutical** alerts: ## Ono Pharmaceutical Stock Performance The firm has a fifty day simple moving average of $14.02 and a 200 day simple moving average of $12.43. The company has a current ratio of 3.02, a quick ratio of 2.56 and a debt-to-equity ratio of 0.10. The stock has a market cap of $8.77 billion, a price-to-earnings ratio of 20.98 and a beta of 0.25. Ono Pharmaceutical (OTCMKTS:OPHLF - Get Free Report) last announced its quarterly earnings data on Monday, February 2nd. The company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.11. The company had revenue of $892.70 million for the quarter, compared to analyst estimates of $727.58 million. Ono Pharmaceutical had a return on equity of 7.76% and a net margin of 12.29%. ## Ono Pharmaceutical Company Profile (Get Free Report) Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development. One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo. ## Recommended Stories - Five stocks we like better than Ono Pharmaceutical - Your Bank Account Is No Longer Safe - Nvidia CEO Issues Bold Tesla Call - NEW LAW: Congress Approves Setup For Digital Dollar? - Buy this Gold Stock Before May 2026 - What a Former CIA Agent Knows About the Coming Collapse _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Ono Pharmaceutical Right Now? Before you consider Ono Pharmaceutical, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ono Pharmaceutical wasn't on the list. While Ono Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [OPHLY.US](https://longbridge.com/en/quote/OPHLY.US.md) - [4528.JP](https://longbridge.com/en/quote/4528.JP.md) ## Related News & Research - [Ono Pharmaceutical (TSE:4528) Earnings Growth Versus Forecast Declines Tests Bull And Bear Narratives](https://longbridge.com/en/news/285822299.md) - [KOALA trial opens to enrol patients for first‑in‑human KMCAR T‑cell therapy](https://longbridge.com/en/news/287059695.md) - [06:31 ETNetherton Syndrome Market Set to Expand During the Forecast Period (2026-2036) as Novel Therapies Enter Development Pipeline | DelveInsight](https://longbridge.com/en/news/286895360.md) - [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md) - [FACTBOX-Bundibugyo Ebola vaccines and treatments in development](https://longbridge.com/en/news/287257711.md)